These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22930887)

  • 1. Nuclear medicine imaging of neuroendocrine tumours.
    Al-Nahhas A
    Clin Med (Lond); 2012 Aug; 12(4):377-80. PubMed ID: 22930887
    [No Abstract]   [Full Text] [Related]  

  • 2. Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?
    Öberg K
    Endocrine; 2012 Aug; 42(1):3-4. PubMed ID: 22562721
    [No Abstract]   [Full Text] [Related]  

  • 3. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.
    Wild D; Mäcke HR; Waser B; Reubi JC; Ginj M; Rasch H; Müller-Brand J; Hofmann M
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):724. PubMed ID: 15551131
    [No Abstract]   [Full Text] [Related]  

  • 4. Should we stop offering indium-111 octreotide scans in favour of gallium-68 PET-CT scans in the UK?
    Kalsy N; Vinjamuri S
    Nucl Med Commun; 2016 Dec; 37(12):1221-1222. PubMed ID: 27612035
    [No Abstract]   [Full Text] [Related]  

  • 5. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
    Henze M; Schuhmacher J; Dimitrakopoulou-Strauss A; Strauss LG; Mäcke HR; Eisenhut M; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):466. PubMed ID: 14730407
    [No Abstract]   [Full Text] [Related]  

  • 6. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
    Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
    Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
    Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
    J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor imaging: current status and future perspectives.
    Bohuslavizki KH
    J Nucl Med; 2001 Jul; 42(7):1057-8. PubMed ID: 11438628
    [No Abstract]   [Full Text] [Related]  

  • 10. Gallium-68 PET: a new frontier in receptor cancer imaging.
    Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D
    Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin Receptor Scintigraphy: Blazing in Indium and Quenching in Gallium.
    Bodei L
    J Nucl Med; 2020 Dec; 61(Suppl 2):121S-122S. PubMed ID: 33293432
    [No Abstract]   [Full Text] [Related]  

  • 12. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies.
    Lincke T; Singer J; Kluge R; Sabri O; Paschke R
    Thyroid; 2009 Apr; 19(4):381-9. PubMed ID: 19355828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
    Treglia G; Castaldi P; Rindi G; Giordano A; Rufini V
    Endocrine; 2012 Aug; 42(1):80-7. PubMed ID: 22350660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tumor with an atypical clinical course: a description of 2 cases.
    Arrue I; Arregui MA; Catón B; Soloeta R
    Actas Dermosifiliogr; 2014; 105(1):94-6. PubMed ID: 23260877
    [No Abstract]   [Full Text] [Related]  

  • 15. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor uptake of 68Ga-DOTA-Tyr3-octreotate: animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model.
    Hanin FX; Pauwels S; Bol A; Breeman W; de Jong M; Jamar F
    Nucl Med Biol; 2010 Feb; 37(2):157-65. PubMed ID: 20152715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
    Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
    Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applications of Gallium-68.
    Banerjee SR; Pomper MG
    Appl Radiat Isot; 2013 Jun; 76():2-13. PubMed ID: 23522791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.